Central Nervous System Lymphoma
📧 Sign up to get email alerts when something new happens for Central Nervous System Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-08-15Clinical Trial Update: A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial is evaluating Pomadomide in combination with Rituximab and Methotrexate for newly diagnosed primary central…
-
CLINICAL_TRIALS trial_result · 2024-07-30Clinical Trial Update: First-line Treatment of PCNSL With the Combination of Orelabrutinib, Rituximab, and Methotrexate (ORM Regimen) [Phase 2]
A Phase 2 trial evaluating the ORM regimen (Orelabrutinib, Rituximab, and Methotrexate) as first-line therapy for primary central nervous sy…
-
CLINICAL_TRIALS research · 2024-06-06Clinical Trial Update: A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSL [NA]
The document describes a clinical study evaluating the safety and efficacy of the ZRMT Regimen for Primary Central Nervous System Lymphoma, …
-
CLINICAL_TRIALS trial_result · 2024-04-01Clinical Trial Update: Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma [Phase 2]
Phase 2 trial evaluating rituximab, methotrexate, procarbazine, and vincristine followed by high-dose chemotherapy with autologous stem-cell…
-
CLINICAL_TRIALS trial_result · 2023-11-28Clinical Trial Update: Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas [Phase 2]
Phase 2 trial of pembrolizumab in relapsed/refractory gray-zone lymphoma, primary CNS lymphoma, and other extranodal diffuse large B-cell ly…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-09-05Clinical Trial Update: Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT [Phase 2]
Phase 2 clinical trial evaluating zanubrutinib with rituximab and chemotherapy for newly diagnosed primary central nervous system lymphoma i…
-
CLINICAL_TRIALS trial_result · 2022-11-23Clinical Trial Update: Rituximab,Methotrexate and Lenalidomide in Newly Diagnosed Primary Central Nervous System Lymphoma [Phase 2]
Phase 2 trial evaluating rituximab, methotrexate, and lenalidomide in newly diagnosed primary central nervous system lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2022-11-21Clinical Trial Update: Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Clinical trial update on ublituximab for relapsed or refractory B-cell non-Hodgkin lymphoma completed phases 1 and 2.
-
CLINICAL_TRIALS trial_result · 2022-11-08Clinical Trial Update: Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma [Phase 2]
A Phase 2 trial evaluating rituximab plus methotrexate with or without lenalidomide in newly diagnosed primary central nervous system lympho…
-
CLINICAL_TRIALS trial_result · 2022-10-12Clinical Trial Update: A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL [Phase 2]
Phase 2 trial update for ICP-022 in patients with relapsed/refractory primary CNS lymphoma and secondary CNS lymphoma.
-
CLINICAL_TRIALS trial_result · 2022-08-04Clinical Trial Update: Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma [Phase 2]
A Phase 2 clinical trial update for newly diagnosed primary central nervous system lymphoma conducted in Nordic centers has completed enroll…
-
CLINICAL_TRIALS trial_result · 2022-06-09Clinical Trial Update: Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases [NA]
Trial update for Ferumoxytol assessing its utility in improving MR imaging for high-grade brain tumors and cerebral metastases; study comple…
-
CLINICAL_TRIALS trial_result · 2022-06-02Clinical Trial Update: A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma [Phase 1, Phase 2]
Clinical trial investigating BTK inhibitor, PD-1, and Formustine as first-line therapy for primary CNS lymphoma (Phase 1/2).
-
CLINICAL_TRIALS trial_result · 2022-05-31Clinical Trial Update: R-MTX-zanbrutinib in Secondary CNS Lymphoma [Phase 2]
Phase 2 trial update for R-MTX-zanbrutinib in Secondary Central Nervous System Lymphoma.
-
CLINICAL_TRIALS trial_result · 2022-05-25Clinical Trial Update: Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL [Phase 2]
Phase 2 clinical trial evaluating sequential RO-MTX after therapy with pomalidomide, orelabrutinib, and rituximab (POR) in newly diagnosed p…
-
CLINICAL_TRIALS trial_result · 2022-05-10Clinical Trial Update: Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma [Phase 2]
Phase 2 trial investigating ibrutinib as maintenance therapy in elderly patients with central nervous system lymphoma.
-
CLINICAL_TRIALS trial_result · 2022-04-19Clinical Trial Update: Orelabrutinib Maintenance Therapy After ASCT in Primary Central Nervous System Lymphoma [Phase 3]
Phase 3 trial update investigating maintenance therapy with orelabrutinib after autologous stem cell transplant in primary central nervous s…
-
CLINICAL_TRIALS trial_result · 2022-04-07Clinical Trial Update: Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma [Phase 2]
Phase 2 clinical trial evaluating the combination of ibrutinib with methotrexate and temozolomide for newly diagnosed primary central nervou…
-
CLINICAL_TRIALS trial_result · 2022-04-04Clinical Trial Update: Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
Clinical trial update for ONC201 in relapsed/refractory non-Hodgkin's lymphoma, including phase 1 and phase 2 cohorts; study status terminat…
-
CLINICAL_TRIALS trial_result · 2022-03-10Clinical Trial Update: Treatment of Primary CNS Lymphoma ( FTD ) [Phase 2]
Phase 2 clinical trial update for treatment of Primary CNS Lymphoma (PCNSL) completed.
-
CLINICAL_TRIALS trial_result · 2022-03-02Clinical Trial Update: Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma [Phase 3]
A Phase 3 trial comparing maintenance treatment versus observation in elderly patients with primary central nervous system lymphoma.
-
CLINICAL_TRIALS trial_result · 2021-09-23Clinical Trial Update: Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL [Phase 3]
A Phase 3 trial evaluates intermediate-dose intravenous methotrexate as central nervous system prophylaxis for high-risk diffuse large B-cel…
-
CLINICAL_TRIALS trial_result · 2021-09-22Clinical Trial Update: Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma [Phase 1, Phase 2]
Phase 1/2 clinical trial investigating a combination regimen (methotrexate, mannitol, rituximab, and carboplatin) for newly diagnosed primar…
-
CLINICAL_TRIALS trial_result · 2021-07-16Clinical Trial Update: A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) [Phase 2]
Phase 2 trial comparing ibrutinib versus lenalidomide in combination with MRE-chemotherapy for adult patients with recurrent or refractory p…
-
CLINICAL_TRIALS trial_result · 2021-06-24Clinical Trial Update: Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma [Phase 2]
Phase 2 clinical trial evaluating rituximab, zanubrutinib, and lenalidomide with subsequent maintenance in CNS lymphoma.